News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–48
Matches
48
Sources here
7
Companies here
1
Search results Stored financial headlines

Active search

48 matching headlines

Ticker or company: AORTMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

TradingKey Earnings Main company 🇺🇸 United States

Artivion Inc (AORT) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Artivion Inc (AORT), listing its major shareholders and their respective proportions, including BlackRock Institutional Trust Company, N.A., Nomura Investment Management Business Trust, and Fidelity Management & Research Company LLC. It also provides a breakdown of shareholder types, …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Artivion, Inc. Revenue Breakdown – SWB:CYL

Artivion, Inc. (SWB:CYL) generated a total revenue of ‪375.76 M‬ EUR last year. The Medical Devices segment was the top-performing segment, contributing ‪294.44 M‬ EUR, an increase from the previous year. The United States was the largest regional contributor to the company's revenue, accounting …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

AORT|Artivion Inc|Price:25.280|Chg%:+0.280

Artivion Inc (AORT) is trading at 25.280 USD, up 1.12% with a market cap of 1.23 billion. The company, which specializes in medical devices for aortic diseases, shows healthy fundamentals and high growth potential, though its valuation is considered fairly valued within its industry. …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Artivion, Inc. Revenue Breakdown – LS:900006

Artivion, Inc. generated 375.76 million EUR in revenue last year, with its Medical Devices segment being the top-performer, bringing in 294.44 million EUR. The United States was the largest geographical contributor, accounting for 182.27 million EUR of the company's revenue. This financial breakdown provides …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results

Artivion, Inc. (AORT) will release its second-quarter 2026 financial results on Thursday, August 6, 2026, after the market closes. The company will host a teleconference call and webcast at 4:30 p.m. ET to discuss these results, followed by a Q&A session with Chairman, President, …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Artivion schedules Q2 results webcast for Aug. 6 at 4:30 p.m.

Artivion (NYSE: AORT) announced it will release its second quarter 2026 financial results on Thursday, August 6, 2026, after the market closes. The company will host a teleconference and live webcast on the same day at 4:30 p.m. ET, which will include a Q&A …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Earnings Main company 🇺🇸 United States

Does Slower AMDS Uptake Recast Artivion’s Core Growth Narrative (AORT)

Artivion (AORT) recently reported Q1 results in line with expectations but reduced its full-year outlook due to slower-than-anticipated sales of its AMDS aortic device starter sets. This has raised concerns about the company's core growth narrative, despite the FDA's June 2026 PMA approval for …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
AlphaStreet Earnings Main company 🇺🇸 United States

Artivion (AORT) Grew in Q1, but AMDS Timing and Lower 2026 Targets Still Softened the Story

Artivion (AORT) reported strong Q1 2026 financial results with significant revenue and adjusted EBITDA growth. However, the company lowered its full-year 2026 guidance due to "transient factors" and slower-than-expected AMDS product timing, concerning investors. While other product categories showed robust growth, the revised outlook …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Analyst action Main company 🇺🇸 United States

Citizens reiterates Artivion stock rating citing FDA approval benefits

Citizens has reiterated a Market Outperform rating and a $48.00 price target for Artivion Inc. (NYSE:AORT), citing benefits from recent FDA approval of its AMDS Hybrid Prosthesis platform. Despite a year-to-date stock decline, the company expects momentum to build in late 2026 and 2027 …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Simply Wall Street Guidance Main company 🇺🇸 United States

Artivion (AORT) Cuts Guidance Following AMDS Slower Adoption, Is It Still Below Fair Value?

Artivion (AORT) recently cut its full-year guidance due to slower-than-expected adoption of its AMDS product, despite reporting 12% non-GAAP constant currency revenue growth in Q1 2026. This has led to a significant share price drop, though a popular narrative values the stock at $42, …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Deals and strategy Main company 🇺🇸 United States

Needham reiterates Artivion stock rating on product cycle outlook

Needham has reiterated a Buy rating and a $44.00 price target for Artivion Inc. (NYSE:AORT), citing a significant product cycle driven by its AMDS and upcoming NEXUS products. The firm expects these products to boost revenue growth and adjusted EBITDA, anticipating a reacceleration of …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quartr Earnings Main company 🇺🇸 United States

Artivion (AORT) Corporate presentation Summary

Artivion (AORT) presented a summary of its financial performance, growth strategies, and product innovation, highlighting its specialization in aortic disease. The company reported FY25 revenue of $444 million and projected FY26 revenue of $480–496 million, with strong EBITDA growth and reduced net debt. Key …

AORT main company
Sharemaestro market context Price below Trend Line 52 weeks -35.0% AORT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context